Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins.
Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.